Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis.
animal models
meta-analysis
schizophrenia
social deficits
social interaction test
treatment
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
18 11 2022
18 11 2022
Historique:
pubmed:
5
8
2022
medline:
22
11
2022
entrez:
4
8
2022
Statut:
ppublish
Résumé
While pharmacological treatments for positive symptoms of schizophrenia are widely used, their beneficial effect on negative symptoms, particularly social impairment, is insufficiently studied. Therefore, there is an increasing interest in preclinical research of potentially beneficial treatments, with mixed results. The current review aims to evaluate the efficacy of available treatments for social deficits in different animal models of schizophrenia. A systematic literature search generated 145 outcomes for the measures "total time" and "number" of social interactions. Standardized mean differences (SMD) and 95% confidence interval (CI) were calculated, and heterogeneity was tested using Q statistics in a random-effect meta-analytic model. Given the vast heterogeneity in effect sizes, the animal model, treatment group, and sample size were all examined as potential moderators. The results showed that in almost all models, treatment significantly improved social deficit (total time: SMD = 1.24; number: SMD = 1.1). The moderator analyses discovered significant subgroup differences across models and treatment subgroups. Perinatal and adult pharmacological models showed the most substantial influence of treatments on social deficits, reflecting relative pharmacological validity. Furthermore, atypical antipsychotic drugs had the highest SMD within each model subgroup. Our findings indicate that the improvement in social interaction behaviors is dependent on the animal model and treatment family used. Implications for the preclinical and clinical fields are discussed.
Sections du résumé
BACKGROUND
While pharmacological treatments for positive symptoms of schizophrenia are widely used, their beneficial effect on negative symptoms, particularly social impairment, is insufficiently studied. Therefore, there is an increasing interest in preclinical research of potentially beneficial treatments, with mixed results. The current review aims to evaluate the efficacy of available treatments for social deficits in different animal models of schizophrenia.
STUDY DESIGN
A systematic literature search generated 145 outcomes for the measures "total time" and "number" of social interactions. Standardized mean differences (SMD) and 95% confidence interval (CI) were calculated, and heterogeneity was tested using Q statistics in a random-effect meta-analytic model. Given the vast heterogeneity in effect sizes, the animal model, treatment group, and sample size were all examined as potential moderators.
STUDY RESULTS
The results showed that in almost all models, treatment significantly improved social deficit (total time: SMD = 1.24; number: SMD = 1.1). The moderator analyses discovered significant subgroup differences across models and treatment subgroups. Perinatal and adult pharmacological models showed the most substantial influence of treatments on social deficits, reflecting relative pharmacological validity. Furthermore, atypical antipsychotic drugs had the highest SMD within each model subgroup.
CONCLUSIONS
Our findings indicate that the improvement in social interaction behaviors is dependent on the animal model and treatment family used. Implications for the preclinical and clinical fields are discussed.
Identifiants
pubmed: 35925025
pii: 6655717
doi: 10.1093/schbul/sbac093
pmc: PMC9673263
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Review
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1179-1193Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):827-32
pubmed: 15916843
Behav Brain Res. 2016 Sep 15;311:368-374
pubmed: 27247142
Trends Neurosci. 2021 Jun;44(6):464-477
pubmed: 33674134
J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):777-787
pubmed: 29242310
Pharmacol Ther. 2009 May;122(2):150-202
pubmed: 19269307
Encephale. 2001 Jan-Feb;27(1):53-9
pubmed: 11294039
J Clin Psychiatry. 2014 Apr;75(4):e308-16
pubmed: 24813414
Brain Res Bull. 2019 Aug;150:150-159
pubmed: 31129169
Schizophr Bull. 2006 Oct;32 Suppl 1:S44-63
pubmed: 16916889
J Nerv Ment Dis. 2009 Apr;197(4):274-7
pubmed: 19363384
Schizophr Res. 2009 Nov;115(1):41-9
pubmed: 19744833
Behav Brain Res. 2017 Jul 28;331:30-37
pubmed: 28527693
CNS Drugs. 2016 Mar;30(3):193-208
pubmed: 26895254
Behav Brain Res. 2020 Jan 27;378:112305
pubmed: 31634496
J Pharmacol Exp Ther. 2019 Dec;371(3):692-702
pubmed: 31578257
Curr Treat Options Neurol. 2010 Nov;12(6):529-38
pubmed: 20848330
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Neuropsychopharmacology. 2016 Jan;41(2):598-610
pubmed: 26108886
Pharmacol Rep. 2019 Oct;71(5):768-773
pubmed: 31351318
Neuropharmacology. 2012 Mar;62(3):1308-21
pubmed: 21238465
Schizophr Bull. 2012 Nov;38(6):1247-57
pubmed: 22080497
Int Rev Psychiatry. 2010;22(5):417-28
pubmed: 21047156
Annu Rev Pharmacol Toxicol. 2011;51:189-209
pubmed: 20868275
Neuropharmacology. 2002 Mar;42(3):414-20
pubmed: 11897119
Curr Pharm Des. 2011;17(2):137-50
pubmed: 21355834
Trends Neurosci. 2001 Sep;24(9):527-33
pubmed: 11506886
Curr Pharm Des. 2012;18(32):5188-93
pubmed: 22716147
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 2;90:169-176
pubmed: 30500412
J Pharmacol Exp Ther. 2018 Apr;365(1):179-188
pubmed: 29440309
Br J Pharmacol. 2011 Oct;164(4):1162-94
pubmed: 21449915
Behav Pharmacol. 2015 Dec;26(8 Spec No):748-65
pubmed: 26287433
Eur Psychiatry. 2021 Mar 17;64(1):e21
pubmed: 33726883
Acta Neuropsychiatr. 2012 Jun;24(3):130-46
pubmed: 22736892
Psychol Med. 2007 Apr;37(4):595-601
pubmed: 17094815
Braz J Psychiatry. 2013;35 Suppl 2:S132-9
pubmed: 24271225
Schizophr Bull. 2008 Nov;34(6):1211-20
pubmed: 18184635
Rev Neurosci. 1999;10(1):59-90
pubmed: 10356992
Schizophr Res. 1991 Jan-Feb;4(1):23-30
pubmed: 2009253
Schizophr Bull. 2015 Jul;41(4):892-9
pubmed: 25528757
J Neuroinflammation. 2012 Mar 16;9:56
pubmed: 22424389
Int J Neuropsychopharmacol. 2011 Feb;14(1):43-51
pubmed: 20678304
Life Sci. 2020 May 15;249:117535
pubmed: 32151688
Am J Psychiatry. 2005 Sep;162(9):1746-8
pubmed: 16135639
Schizophr Res. 2011 Oct;132(1):50-3
pubmed: 21840177
Psychopharmacology (Berl). 2008 Apr;197(2):217-27
pubmed: 18058088
Int J Mol Sci. 2019 Jun 06;20(11):
pubmed: 31174329
CNS Neurosci Ther. 2010 Jun;16(3):e72-91
pubmed: 20406253
Behav Brain Res. 2020 Aug 5;391:112674
pubmed: 32417274
Neuropsychiatr Dis Treat. 2014 Feb 27;10:417-25
pubmed: 24600227
Pharmacol Res. 2020 Jun;156:104749
pubmed: 32151683
Neuropsychiatr Dis Treat. 2019 Jun 05;15:1525-1535
pubmed: 31239687
P T. 2015 Jun;40(6):389-97
pubmed: 26045648
Arch Gen Psychiatry. 2002 Feb;59(2):154-64
pubmed: 11825137
Br J Psychiatry. 2005 Jan;186:18-25
pubmed: 15630119
World J Psychiatry. 2021 Aug 19;11(8):463-476
pubmed: 34513608
Biol Psychiatry. 2016 Jun 15;79(12):952-61
pubmed: 26444072
PLoS One. 2015 Mar 24;10(3):e0119258
pubmed: 25803852
Schizophr Res. 2005 Dec 1;80(1):85-97
pubmed: 16183258
Eur Neuropsychopharmacol. 2014 Jun;24(6):846-55
pubmed: 24636461
Neuropsychopharmacology. 2005 Oct;30(10):1883-94
pubmed: 15798779
Neurochem Int. 2019 Sep;128:127-134
pubmed: 30998952
Schizophr Res. 2015 May;164(1-3):155-63
pubmed: 25680767
Br J Psychiatry. 2007 May;190:379-84
pubmed: 17470951
Int J Mol Sci. 2013 Apr 25;14(5):9037-50
pubmed: 23698762
Schizophr Res. 2020 Jan;215:408-415
pubmed: 31471246
J Clin Psychiatry. 2006;67 Suppl 5:19-23
pubmed: 16822093
Front Psychiatry. 2018 Apr 24;9:157
pubmed: 29740360
Brain Behav Immun. 2019 Oct;81:574-587
pubmed: 31326506
Int J Neuropsychopharmacol. 2014 May;17(5):723-37
pubmed: 24345457
Pharmacol Biochem Behav. 2012 Nov;103(1):119-55
pubmed: 22841890
Acta Psychiatr Scand. 2002 Nov;106(5):323-30
pubmed: 12366465
Behav Brain Res. 2009 Dec 7;204(2):295-305
pubmed: 19100784
Discov Med. 2012 Dec;14(79):413-20
pubmed: 23272693
Front Endocrinol (Lausanne). 2015 Jun 03;6:90
pubmed: 26089815
Psychiatry Res. 2009 Jun 30;172(3):180-3
pubmed: 19386475
Genes Brain Behav. 2019 Jan;18(1):e12525
pubmed: 30311398
Psychopharmacology (Berl). 1999 Jul;145(2):193-204
pubmed: 10463321
Braz J Psychiatry. 2008 Sep;30(3):271-80
pubmed: 18833429
Neuropsychopharmacology. 2008 May;33(6):1266-75
pubmed: 17637609
Front Pharmacol. 2017 Jun 21;8:399
pubmed: 28680405
Mol Psychiatry. 2005 Jan;10(1):79-104
pubmed: 15289815
Neurobiol Dis. 2013 May;53:61-74
pubmed: 23142533
Front Pharmacol. 2018 Aug 21;9:901
pubmed: 30186164
Metab Brain Dis. 2017 Oct;32(5):1475-1489
pubmed: 28508340
Am J Psychiatry. 1997 Dec;154(12):1648-54
pubmed: 9396941
Am J Psychiatry. 2004 Feb;161(2):364-7
pubmed: 14754789
J Psychiatr Res. 2013 Aug;47(8):1061-8
pubmed: 23628387
Pharmacopsychiatry. 2010 Jun;43(4):122-9
pubmed: 20309809
Curr Top Med Chem. 2016;16(29):3385-3403
pubmed: 27291902
Neurosci Biobehav Rev. 2013 Nov;37(9 Pt B):2166-80
pubmed: 24090822
Mol Psychiatry. 2017 Oct;22(10):1492-1501
pubmed: 27480492
Psychopharmacology (Berl). 2017 Sep;234(18):2707-2725
pubmed: 28612134
Schizophr Bull. 2008 May;34(3):408-11
pubmed: 18375928
Int J Neuropsychopharmacol. 2010 Apr;13(3):373-86
pubmed: 19607756
Eur Neuropsychopharmacol. 2014 May;24(5):759-73
pubmed: 24342774
Prog Neurobiol. 2010 Mar;90(3):285-326
pubmed: 19857543
Psychoneuroendocrinology. 2017 Jan;75:141-151
pubmed: 27825069
Schizophr Bull. 2009 Jan;35(1):256-78
pubmed: 18245062
Aust N Z J Psychiatry. 2008 Aug;42(8):678-85
pubmed: 18622775
Psychiatry Res. 2010 Jun 30;178(1):46-50
pubmed: 20452678
Exp Neurol. 2018 Jul;305:1-12
pubmed: 29554474
Mol Psychiatry. 2020 Apr;25(4):896-905
pubmed: 30692610
Adv Neurobiol. 2017;17:385-409
pubmed: 28956340
Br J Pharmacol. 2020 Jul;177(14):3210-3224
pubmed: 32133633
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Behav Neural Biol. 1980 Oct;30(2):197-206
pubmed: 7447871
Clin Psychol Rev. 2013 Dec;33(8):914-28
pubmed: 23988452
Psychopharmacology (Berl). 2004 Nov;176(3-4):312-9
pubmed: 15179541
Schizophr Bull. 2018 Oct 17;44(6):1195-1203
pubmed: 29762765
Schizophr Bull. 2017 Oct 21;43(6):1291-1303
pubmed: 28586471
Neuropsychopharmacology. 2015 Nov;40(12):2764-73
pubmed: 25936642
Clin Schizophr Relat Psychoses. 2010 Jul;4(2):124-37
pubmed: 20643635
Recent Pat CNS Drug Discov. 2014 Apr;9(1):13-25
pubmed: 24605939
Behav Brain Res. 2014 Oct 15;273:63-72
pubmed: 25064467
Cereb Cortex. 2003 Jul;13(7):736-48
pubmed: 12816889
Br J Clin Pharmacol. 2001 Apr;51(4):317-24
pubmed: 11318766
Trends Neurosci. 2017 Jul;40(7):385-396
pubmed: 28554687
CNS Neurosci Ther. 2018 Jul;24(7):624-632
pubmed: 29656549
Neuropsychopharmacology. 2012 Mar;37(4):929-38
pubmed: 22089319
PLoS One. 2014 Jun 16;9(6):e100188
pubmed: 24932798
Psychopharmacology (Berl). 2016 May;233(10):1765-77
pubmed: 26728894
Schizophr Bull. 2012 Sep;38(5):958-66
pubmed: 22987851
J Pharmacol Exp Ther. 2019 Oct;371(1):1-14
pubmed: 31371483
Arch Gen Psychiatry. 1989 Aug;46(8):745-53
pubmed: 2665688
Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):567-78
pubmed: 25895634
Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):337-49
pubmed: 15133589
Psychiatry Res. 2014 Nov 30;219(3):680-6
pubmed: 25042426
J Clin Psychopharmacol. 2014 Feb;34(1):124-8
pubmed: 24346752
J Clin Epidemiol. 2001 Oct;54(10):1046-55
pubmed: 11576817
Neurosci Biobehav Rev. 2011 Jan;35(3):573-88
pubmed: 20620163
Br J Psychiatry. 2010 Sep;197(3):174-9
pubmed: 20807960
Neuropharmacology. 2019 Mar 1;146:212-221
pubmed: 30496751
Pharmacol Biochem Behav. 2003 Aug;76(1):1-8
pubmed: 13679211
Psychopharmacology (Berl). 1995 Jul;120(1):67-74
pubmed: 7480537
J Clin Psychopharmacol. 2005 Dec;25(6):570-4
pubmed: 16282840
Asian J Psychiatr. 2013 Apr;6(2):119-23
pubmed: 23466107
Lancet. 1995 Aug 19;346(8973):477-81
pubmed: 7637483
Psychopharmacology (Berl). 2015 Aug;232(15):2849-61
pubmed: 25869273
Am J Psychiatry. 2020 Sep 1;177(9):868-872
pubmed: 32867516
Behav Brain Res. 2002 Mar 10;130(1-2):191-6
pubmed: 11864734
Neurochem Res. 2016 Aug;41(8):2049-64
pubmed: 27097547
Biol Psychiatry. 2006 Aug 1;60(3):253-64
pubmed: 16581031
Peptides. 2017 Nov;97:8-15
pubmed: 28882471
Neuropharmacology. 2019 May 15;150:1-14
pubmed: 30831160
Eur J Neurosci. 2002 Jan;15(1):120-32
pubmed: 11860512
Schizophr Res. 2014 Mar;153(1-3):150-9
pubmed: 24556469
Schizophr Res. 2009 Aug;113(1):72-6
pubmed: 19545977
J Neurosci Res. 2012 Jan;90(1):288-306
pubmed: 21932359
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
Biol Rev Camb Philos Soc. 2007 Nov;82(4):591-605
pubmed: 17944619
Psychiatry. 1990 Nov;53(4):340-5
pubmed: 2263677
Arch Gen Psychiatry. 2012 Aug;69(8):776-86
pubmed: 22474070
Neuropharmacology. 2012 Mar;62(3):1544-53
pubmed: 21156184
Behav Brain Res. 2011 Oct 10;224(1):135-9
pubmed: 21669233
Behav Brain Res. 2011 Nov 20;225(1):15-22
pubmed: 21741413
Clin Ther. 2010 Feb;32(2):275-92
pubmed: 20206786
Annu Rev Clin Psychol. 2013;9:409-33
pubmed: 23245340
CNS Drugs. 2008;22(12):983-93
pubmed: 18998737
J Grad Med Educ. 2012 Sep;4(3):279-82
pubmed: 23997866
J Comp Neurol. 2019 Feb 1;527(2):362-371
pubmed: 30255933
Am J Psychiatry. 2006 Nov;163(11):1918-25
pubmed: 17074943
Schizophr Bull. 2010 Jan;36(1):48-70
pubmed: 19955389
Cell Tissue Res. 2013 Oct;354(1):107-18
pubmed: 23760888
Nat Neurosci. 2010 Oct;13(10):1161-9
pubmed: 20877280
Isr J Psychiatry Relat Sci. 2010;47(1):4-16
pubmed: 20686195
Psychol Med. 2015 Feb;45(3):453-65
pubmed: 24993642
Iran J Psychiatry Behav Sci. 2015 Sep;9(3):e853
pubmed: 26576178
Biol Psychiatry. 2016 Apr 1;79(7):604-12
pubmed: 26852073
Am J Psychiatry. 2002 Feb;159(2):217-26
pubmed: 11823263
Schizophr Bull. 2012 Sep;38(5):1092-104
pubmed: 21525166
Schizophr Bull. 2008 Mar;34(2):322-9
pubmed: 18199631
Nucl Med Biol. 2014 Sep;41(8):681-7
pubmed: 24927927
Neuropsychopharmacology. 2017 Jun;42(7):1447-1457
pubmed: 28230072
Mol Psychiatry. 2019 Aug;24(8):1135-1156
pubmed: 30816289
J Neural Transm (Vienna). 2019 Nov;126(11):1383-1408
pubmed: 31584111
Schizophr Bull. 2010 Jan;36(1):71-93
pubmed: 19955390
Biomed Pharmacother. 2017 Aug;92:373-383
pubmed: 28554133
Int J Mol Sci. 2017 Aug 03;18(8):
pubmed: 28771182
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jul 13;85:16-22
pubmed: 29625156
Ther Adv Psychopharmacol. 2015 Feb;5(1):43-58
pubmed: 25653831
Biol Psychiatry. 2001 Dec 1;50(11):912-24
pubmed: 11743945
J Clin Psychiatry. 2016 Feb;77 Suppl 2:8-11
pubmed: 26919052
Neuropharmacology. 2007 Mar;52(4):1179-87
pubmed: 17313962
Pharmacol Rep. 2015 Dec;67(6):1183-7
pubmed: 26481539